RecallRadar

FDA Drug recall D-1217-2018

Synjardy (empagliflozin and metformin hydrochloride) Tablets. 5 mg/1000 mg

On 2018-10-03 the FDA classified a Class II recall of Synjardy (empagliflozin and metformin hydrochloride) Tablets. 5 mg/1000 mg by Boehringer Ingelheim Pharmaceuticals, citing cross Contamination With Other Products:.

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-1217-2018
ClassificationClass II
Statusterminated
Initiated2018-09-04
Published2018-10-03
Last updated2026-09-13 11:52 UTC
CompanyBoehringer Ingelheim Pharmaceuticals
DistributionUS

Product

Synjardy (empagliflozin and metformin hydrochloride) Tablets. 5 mg/1000 mg. Rx only. 180-count bottle. Distributed by: Boehinger Ingelheim (BI) Pharmaceuticals, Inc. Ridgefield, CT 06877. Made in Germany. Marketed by: BI Pharmaceuticals, Inc. Ridgefield, CT 06877 and Eli Lilly and Company Indianapolis IN 46285 NDC 0597-0175-18

Reason

Cross Contamination With Other Products:

Identifiers

ndc0597-0159-60
ndc0597-0159-18
ndc0597-0159-66
ndc0597-0175-60
ndc0597-0175-18
ndc0597-0175-66
ndc0597-0180-60
ndc0597-0180-18
ndc0597-0180-66
ndc0597-0168-60
ndc0597-0168-18
ndc0597-0168-66
code_infoLot # 603968 EXP 4/2019

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1217-2018%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.